VivoSim Labs, Inc. (NASDAQ: VIVS), a pharmaceutical and biotechnology services company specializing in 3D human tissue models, announced it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds. The private placement consists of 4,705,883 shares of common stock or common stock equivalents, along with accompanying warrants, priced at a combined $0.85 per share. The warrants are exercisable following shareholder approval and expire five years after their initial exercise date, carrying an exercise price of $0.85 per share.
In addition to the new warrants, VivoSim agreed, subject to shareholder approval, to amend certain existing May 2024 warrants by reducing their exercise price from $9.60 to $0.85 per share. This adjustment aligns the terms of the older warrants with the new offering, potentially encouraging exercise and providing additional capital. The offering is expected to close on or about July 17, 2026, subject to customary closing conditions.
VivoSim intends to use the net proceeds for working capital and general corporate purposes. The securities were offered in a private placement exempt from Securities Act registration requirements, and the company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission covering the shares and warrant shares issued in the transaction.
The significance of this funding round lies in its potential to accelerate VivoSim's mission of providing toxicology testing using 3D human tissue models. The company's new approach methodologies (NAM) offer an alternative to traditional animal testing, particularly for liver and intestinal toxicology insights. This aligns with the U.S. Food and Drug Administration's (FDA) Roadmap to refine animal testing requirements in favor of non-animal NAM methods. As regulatory bodies increasingly emphasize human-relevant models, VivoSim's technology could see accelerated adoption.
For business leaders, this development underscores a growing trend in the pharmaceutical industry toward more ethical and potentially more predictive testing methods. Investors may view the involvement of a healthcare-focused institutional investor as a vote of confidence in VivoSim's technology and market potential. The reduced warrant exercise price could also signal alignment of interests between the company and its investors, potentially leading to further capital infusion if warrants are exercised.
VivoSim Labs operates from San Diego, CA. For more information, visit the company's website at https://vivosim.ai/.
